GleamWall
中文EN

FENC FENNEC PHARMACEUTICALS INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—

Returns

ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x

Cash quality & payout

Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$44.64M$47.54M
R&D expense$250,000$307,000
SG&A expense$28.29M$23.05M
Operating income-$6.28M$2.57M
Interest expense$2.08M$4.07M
Pretax income-$9.63M-$71,000
Income tax$106,000$365,000
Net income-$9.74M-$436,000
EPS (basic)-0.34-0.02
EPS (diluted)-0.34-0.02
Weighted avg. shares (diluted)28.58M27.29M
Balance sheet
Cash & equivalents$36.79M$26.63M
Current assets$67.04M$44.12M
Total assets$70.55M$44.95M
Current liabilities$10.52M$6.92M
Long-term debt—$19.34M
Total debt—$19.34M
Total liabilities$35.08M$50.82M
Shareholders' equity$35.47M-$5.87M
Net debt—-$7.30M
Shares outstanding34.16M27.53M
Cash flow statement
Operating cash flow-$12.47M$26.98M
Financing cash flow$22.63M-$13.62M
Stock-based compensation$7.03M$5.06M

Free plan shows the latest 2 periods; Pro shows all 28 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.